Fineotex Chemical Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹4,849 Cr
- Book Value
- ₹7.58
- Stock P/E
- 39.28
- Dividend Yield
- 0.19%
- ROE
- 13.50%
- ROCE
- 18.30%
- PEG Ratio
- —
- EV/EBITDA
- —
Fundamentals from Screener.in, as of 6 Aug 2026. Live price via Yahoo Finance.
Fineotex Chemical share price today
Fineotex Chemical Ltd (NSE: FCL) is changing faster than its historical label suggests. The company built its franchise in textile auxiliaries and performance chemicals, then expanded into cleaning, water treatment and other applications. Its controlling investment in the US-based CrudeChem Technologies ecosystem has added oilfield chemicals, a much larger revenue base and a new set of operating, integration and capital-allocation risks.
Gale’s 6 August 2026 internal snapshot recorded a post-corporate-action price of ₹41.64 and market capitalisation of ₹4,849 crore. The stored universe row was intentionally sparse and had no valuation or thesis judgment. This article therefore publishes no rating and no paid buy range. It builds a transparent EPS sensitivity from company filings and Screener, while leaving the qualitative internal decision open for review.
Fineotex is now a two-engine specialty-chemicals platform
The legacy business develops formulations used in textile processing, home and personal care, construction, water treatment, leather, paint and adjacent industries. These products are small in the customer’s total cost but can affect finish, colour, process time, water use and rejection rates. That supports technical relationships and a broad catalogue rather than pure commodity sales.
CrudeChem adds chemicals used in drilling, completion, production, stimulation, water management and other oilfield processes. The economics are different: customers require technical performance under demanding field conditions, but revenue can respond to energy activity and project timing.
| Platform | What it supplies | Competitive advantage | Main risk |
|---|---|---|---|
| Textile specialties | Pre-treatment, dyeing, printing and finishing auxiliaries | Formulation library, application support and customer approvals | Textile cycle and pricing competition |
| Home, hygiene and water | Cleaning, disinfection and treatment chemistries | Cross-selling and diversification | Fragmented demand and lower differentiation |
| Construction, paint and leather | Process and performance additives | Customisation across end uses | Slow qualification and small product scale |
| CrudeChem oilfield platform | Fluid additives and production chemicals | US R&D, field knowledge and global customer access | Oil cycle, integration and environmental liability |
The combination can reduce dependence on Indian textiles, but diversification only creates value if Fineotex controls working capital, preserves margin and integrates acquired management without losing customers.
Q1 FY27 revenue transformed; margins became harder to compare
The July 2026 investor presentation reported consolidated revenue from operations of ₹376.63 crore, up 167% from ₹141.07 crore a year earlier. EBITDA excluding other income rose to ₹59.14 crore and PAT to ₹48.21 crore. The acquisition drove much of the scale increase, so the growth rate should not be read as organic.
| Consolidated Q1 measure | Q1 FY26 | Q1 FY27 | Change |
|---|---|---|---|
| Revenue from operations | ₹141.07 Cr | ₹376.63 Cr | +167.1% |
| Gross profit | About ₹46 Cr | ₹133.40 Cr | Acquisition and scale effect |
| Gross margin | 33.53% | 35.42% | +189 bps |
| EBITDA excluding other income | ₹25.20 Cr | ₹59.14 Cr | +134.7% |
| EBITDA margin | 18.38% | 15.70% | -268 bps |
| Profit before tax | ₹31.49 Cr | ₹64.74 Cr | +105.6% approximately |
| Profit after tax | ₹25.03 Cr | ₹48.21 Cr | +92.7% |
| PAT margin | 18.26% | 12.80% | -546 bps approximately |
The quarter contains a healthy gross-margin signal and a weaker operating-margin signal. Acquired oilfield revenue has a different cost structure and the group now carries integration, selling and technical-service costs. The important test is not whether revenue doubled again; it is whether the new mix produces durable cash profit after all group costs.
CrudeChem changes both opportunity and risk
Fineotex acquired a 53.33% controlling interest in four US-based specialty chemical companies forming the CrudeChem ecosystem. Management disclosed a combined acquisition value of roughly US$11.5 million and cited access to R&D, manufacturing, field expertise and global oilfield customers. It also described the transaction as EPS accretive.
Control does not mean ownership of every rupee of profit. Non-controlling interests, purchase accounting, earn-outs and minority protections affect the amount attributable to Fineotex shareholders. The group must also govern a US operation across distance, regulation and culture.
That distinction must remain visible in per-share analysis. Consolidated EBITDA can include the full operating result of a controlled subsidiary, while a minority share of profit belongs to other owners. Analysts should bridge group EBITDA to profit attributable to Fineotex shareholders and then divide by the enlarged share count. Cross-selling is most convincing when it creates repeat customer revenue, attributable cash profit and a stable minority bridge.
The US platform also introduces dollar working capital, product-liability risk and environmental compliance. Receivable ageing, contingent consideration and related-party transactions are essential checks while integration is underway.
| Acquisition test | Value-creating outcome | Warning outcome |
|---|---|---|
| Customer retention | Existing CrudeChem accounts remain and cross-buy | Key relationships depend on former owners |
| Technology transfer | Formulations move between India, Asia and North America | Products remain isolated in separate entities |
| Margin | Group EBITDA margin stabilises after integration | Revenue scale hides weaker unit economics |
| Cash | Receivables and inventory turn normally | Growth consumes cash and requires more equity |
| Governance | Related entities and minorities are transparently reported | Complex structure obscures attributable earnings |
Texas capacity raises the execution bar
During Q1 FY27 the Texas facility added approximately 70,000 MTPA, taking CrudeChem capacity to about 148,000 MTPA. Capacity expansion can support growth and local customer service, but chemical capacity is not earnings until orders, utilisation, yield and pricing convert it.
The oilfield market rewards technical response and product consistency. A plant may make many formulations in campaigns rather than one high-volume commodity. Utilisation therefore needs interpretation alongside product mix. Investors should track sales volume, contribution margin, customer concentration and maintenance capital rather than celebrating nameplate tonnes alone.
Textile chemicals remain the franchise foundation
Fineotex’s legacy product catalogue covers pre-treatment, dyeing, printing and finishing. A chemical may save water, energy or process time, improve colour fastness or help a mill meet an environmental standard. Technical service and successful production trials create switching friction.
Textile customers are still cyclical and price sensitive. Export orders, cotton and synthetic-fibre economics, inventory at brands, and competition from local formulators affect demand. The legacy business must continue generating cash while management focuses on the US platform.
Product breadth is useful only with commercial depth
Screener describes a catalogue of more than 470 chemicals and enzymes serving customers in roughly 70 countries. Breadth allows cross-selling and reduces single-product risk. It can also spread technical and sales resources thinly.
The better measure is revenue per active product family and repeat orders from important customers. A long catalogue has little value if most items remain small or require high inventory. Fineotex should demonstrate that new end uses improve plant loading and working capital rather than merely broaden marketing.
FY26 was already a transition year
Before the full Q1 consolidation, FY26 sales rose to ₹772 crore from ₹533 crore, while operating profit increased only modestly to ₹135 crore from ₹127 crore. Net profit rose to ₹125 crore. The operating margin fell from 24% to 17%, showing that scale and mix were changing before the latest quarter.
| Consolidated measure, ₹ crore | FY25 | FY26 | Reading |
|---|---|---|---|
| Sales | 533 | 772 | +45% approximately |
| Operating profit | 127 | 135 | Much slower than sales |
| Operating margin | 24% | 17% | Seven-point compression |
| Other income | 24 | 33 | Meaningful support to PBT |
| Depreciation | 9 | 13 | Larger asset base |
| Net profit | 109 | 125 | 15% growth approximately |
| ROCE | 24% | 18% | Capital efficiency declined |
The profit base must be normalised for the much larger share count after corporate actions and acquisition-related issuance. Fineotex fixed 31 October 2025 as the record date to split each old ₹2 share into two ₹1 shares and then issue four bonus shares for every resulting ₹1 share. In effect, one old share became ten current shares. The FY26 result says current and comparative EPS were adjusted for both actions under Ind AS 33. Our ₹41.64 price and ₹1.06 EPS therefore use the same enlarged denominator; combining an old pre-action EPS with the new post-action price would overstate value dramatically.
Working capital is the central financial risk
Screener shows debtor days rising to 137 and working-capital days to about 153 in FY26. The balance sheet also expanded with the acquisition and capital raise. Specialty-chemical sales can require customer credit and inventory, but the change is too large to dismiss.
| Working-capital indicator | FY25 | FY26 | Direction |
|---|---|---|---|
| Debtor days | 102 | 137 | Worse |
| Inventory days | 66 | 78 | More stock held |
| Cash-conversion cycle | 88 days | 133 days | Materially longer |
| Working-capital days | 104 | 153 | Cash tied up for longer |
| Borrowings | Nil | ₹8 Cr | Still low at year end |
| Investments | ₹330 Cr | ₹317 Cr | Liquidity buffer remains |
The group was almost debt free at March 2026, which provides resilience. A long cash cycle can still consume the buffer quickly when revenue triples. Quarterly cash flow, receivable ageing and provisions deserve as much attention as EBITDA.
Capital raising can accelerate growth and dilute owners
Fineotex expanded equity capital materially through corporate actions and acquisition consideration. In August 2026 it also disclosed a board meeting to consider additional equity fundraising. New capital can fund capacity, working capital and acquisitions without stressing debt; it also divides future profit across more shares.
Every proposal should be judged on issue price, use of proceeds and expected incremental return. Raising equity at a strong valuation can be rational, but frequent issuance makes per-share EPS growth harder than company-level profit growth. Our model is explicitly per share.
Gale’s 6 August valuation snapshot
| Snapshot metric | Value used | Interpretation |
|---|---|---|
| Post-action share price | ₹41.64 | Fixed cutoff, not the live quote |
| Market capitalisation | ₹4,849 Cr | Micro-cap band in Gale’s universe |
| Normalized P/E | About 39.3× | Demands integration and growth |
| Book value per share | About ₹7.58 | Reflects the enlarged share base |
| ROE | About 13.5% | Lower than historical levels |
| ROCE | 18.3% | Adequate, needs recovery |
| Dividend yield | About 0.19% | Minor part of the return case |
| Normalized post-action TTM EPS | ₹1.06 | Starting point for scenarios |
The share was only 8.3% below its stored 52-week high. A premium multiple can hold if integration works; it can contract sharply if attributed EPS or cash lags consolidated revenue.
Valuation framework: use post-action EPS
The model compounds ₹1.06 of normalized post-corporate-action TTM EPS and applies an exit P/E. It uses 147/365 of annual growth for the 2026 row from the 6 August cutoff, then one additional full year for each later row. Targets are rounded to the nearest ₹5 and exclude dividends.
| Scenario | Annual EPS growth | Exit P/E | What it assumes |
|---|---|---|---|
| Bear | 8% | 25× | Integration and textile demand disappoint; premium compresses |
| Base | 15% | 35× | CrudeChem grows with partial margin recovery and controlled dilution |
| Bull | 22% | 45× | Cross-selling, Texas utilisation and legacy recovery all work |
The base growth rate is below Q1’s acquisition-driven profit increase. The bull case requires high per-share growth after minorities and any new issuance, not merely a larger consolidated revenue number.
Fineotex Chemical share price target 2026 to 2030
The table is a sensitivity range, not a recommendation. Oilfield activity, textile demand, exchange rates, minority interest and equity issuance can place earnings outside every case. Gale’s internal database has not yet assigned FCL a rating or paid valuation range, so none is implied here.
What would change the thesis
The thesis would improve if CrudeChem retains customers, Texas capacity fills, legacy textile margins stabilise and operating cash follows attributable profit. Transparent disclosure of organic growth and non-controlling interest would make the larger group easier to value.
It would weaken if receivables continue rising, more capital is raised without a clear return, acquired margins deteriorate or legacy customers receive less attention. A gap between consolidated PAT and EPS attributable to Fineotex owners would be especially important.
Quarterly monitoring scorecard
| Question | Constructive evidence | Warning evidence |
|---|---|---|
| Is acquisition growth high quality? | Retention, cross-sales and stable gross margin | Revenue rises while group EBITDA margin falls |
| Is capacity productive? | Texas utilisation and contribution improve | Nameplate tonnes rise without cash profit |
| Is per-share value growing? | EPS outpaces share-count expansion | Dilution absorbs company-level profit growth |
| Is cash conversion improving? | Receivable and working-capital days fall | More equity funds customer credit |
| Is legacy business healthy? | Textile revenue and margin recover | US focus masks domestic weakness |
Should you buy Fineotex Chemical at the current price?
Fineotex now offers a broader platform, technical products, a low-debt balance sheet and exposure to global oilfield demand. It also trades on a demanding normalized multiple while integration, working capital and per-share economics remain in transition. That combination calls for evidence, not a shortcut.
Investors should compare the conservative scenario with their required return and wait for clarity on fundraising and attributable cash flow. Gale has not invented a rating or buy range where the internal review is incomplete.
FAQ
What is the Fineotex Chemical share price target for 2030?
The gated table gives bear, base and bull outcomes from normalized post-action EPS and exit P/E assumptions. It is a framework, not a guaranteed destination.
Why did Fineotex revenue jump in Q1 FY27?
The controlling CrudeChem investment added a large US oilfield-chemicals revenue base. The increase is therefore substantially acquisition-led rather than purely organic growth from the legacy business.
Why does the model use ₹1.06 of EPS?
It is a normalized trailing per-share base after the enlarged share count. Using historical pre-action EPS with the post-action price would be inconsistent.
What is the biggest risk after the US acquisition?
Integration and cash conversion are central. Customer retention, minority interest, environmental obligations, working capital and any further equity issuance all affect value attributable to shareholders.
Is Fineotex debt free?
Borrowings were very low at March 2026, but working-capital demand and further expansion can change that position. Net cash should be monitored quarterly.
When are Fineotex’s next results?
Use Gale’s results calendar and confirm the formal board meeting date through the company’s exchange disclosure.
Related research
- PI Industries share price target
- Elantas Beck India share price target
- Acutaas Chemicals share price target
Sources and methodology
- Fineotex Q1 FY27 investor presentation filed with BSE
- Fineotex official investor-presentation archive
- Fineotex official concall archive
- Fineotex consolidated financials on Screener
Gale’s internal 6 August snapshot supplied the fixed price and market value. Because the database row was sparse, post-action EPS and supporting ratios were cross-checked against the Q1 filing and updated Screener record. Yahoo Finance only supplies the indicative live quote.
This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. Scenario targets are arithmetic, not promises. Verify filings, acquisition accounting and share count, and consult a registered adviser before acting.